A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Abramson Cancer Center at Penn Medicine
Study ID
NCT03519308
Phase
EARLY_PHASE1
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    Before Surgery Wks 1 \&3, After Surgery Wks 1 \&3
  • Nab-Paclitaxel — DRUG
    Wks 1,2,3 before surgery and Wks 1, 2,3 after surgery
  • Gemcitabine — DRUG
    Wks 1,2,3 before surgery and Wks 1,2,3 after surgery
  • Paricalcitol — DRUG
    Wks 1,2,3, 4 before surgery and Wks 1,2,3 after surgery

Study Details

The main purpose of this study is to look at the potential effects of paricalcitol (a drug similar to vitamin D) and nivolumab on pancreatic tumors in patients who are treated with gemcitabine and abraxane. The study will also look at the safety of including paricalcitol and nivolumab as part of the gemcitabine and abraxane chemotherapeutic regimen.

Key Dates

Start date
Jul 29, 2020
Status verified
Mar 2024
Primary completion
Apr 18, 2022
Completion
Apr 18, 2022

Study Design

Enrollment
3 participants (actual)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A
  • Experimental: Arm B

Primary Outcome Measure

Number of Adverse Events [ Time Frame: 18 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Abramson Cancer Center of the University of PennsylvaniaPhiladelphiaPennsylvania19104-

Find similar trials in Philadelphia, PA

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
Abramson Cancer Center of the University of Pennsylvania· Philadelphia, PA

Related Studies